4010 Stone Way, N Suite 120
29 articles with Sound Pharmaceuticals
Sound Pharmaceuticals, Inc. (SPI) is pleased to announce that the FDA has allowed two Phase 2 studies to begin testing ebselen (SPI-1005) in COVID-19 patients. SPI is developing SPI-1005, a novel anti-inflammatory drug which was recently shown to inhibit nCoV2 activity and viral replication. 120 adults with moderate or severe disease will
Sound Pharmaceuticals (SPI) is pleased to announce the filing of an Investigational New Drug Application with the FDA to begin Phase 2 studies to prevent and treat COVID-19
Sound Pharmaceuticals is pleased to announce that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere's Disease (STOPMD-3). This is the first Phase 3 study of an investigational new drug for the treatment of Meniere's Disease (MD), a neurotologic disease involving hearing loss, tinn
Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial
SPI-1005 hits pre-specified endpoints resulting in a significant improvement in hearing loss of 65% and 95% relative to placebo
Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere's Disease clinical trial
Sound Pharmaceuticals is pleased to announce the completion of study enrollment in its Phase 2b clinical trial involving Meniere's Disease.
Sound Pharmaceuticals (SPI) is pleased to announce that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial.
University of Oxford and Sound Pharma Begin Phase II Clinical Trial on Novel Treatment for Bipolar Disorder
University of Oxford and Sound Pharma, are pleased to announce the initiation of a Phase II clinical trial of SPI-1005 for the treatment of patients with bipolar disorder.
Sound Pharmaceuticals, Inc. Announces Positive Phase Ib Results And The Start Of A Phase IIb Clinical Trial In Meniere's Disease
Sound Pharmaceuticals, Inc. Announces $1.6 Million Award From Cystic Fibrosis Foundation Therapeutics, Inc. To Prevent And Treat The Hearing Loss And Tinnitus Associated With Antibiotic Use
Sound Pharmaceuticals, Inc. Announces Two New Executive Hires To Accelerate Its Meniere's Drug Development Program
Sound Pharmaceuticals, Inc. And University of Oxford Collaborate On A New Treatment For Bipolar Disorder
Sound Pharmaceuticals, Inc. Submits Positive Phase 2 Clinical Trial Data On SPI-1005 For The Prevention And Treatment Of Sensorineural Hearing Loss
Sound Pharmaceuticals, Inc. Successfully Completes Its First Phase 2 Clinical Trial With SPI-1005 Involving iPod® or Noise Induced Hearing Loss
Sound Pharmaceuticals, Inc. Release: University of Florida Begins iPod® Trial With SPI-1005 to Prevent Hearing Loss